Who
Zachary Roberts
President and CEO
Company insider
Files Form 4 as: President and CEO, Allogene Therapeutics; Chief Medical Officer, Instil Bio.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $289K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Mar 2021
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,530 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —476,190 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,530 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —476,190 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K35,700 at $1.77 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —718,763 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —203,307 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —718,763 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —203,307 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K35,700 at $1.77 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K26,269 at $1.56 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K26,269 at $1.56 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K18,832 at $1.70 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —614,844 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —173,913 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K27,199 at $1.78 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —494,949 at $0.00 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 22 Jan 2024filed 24 Jan 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code F | $78K24,690 at $3.17 | filing |
| 22 Mar 2023filed 24 Mar 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —148,035 at $0.00 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)ALLO · tickerreport.com · 24 Oct 2026Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Zachary Roberts; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.